Literature DB >> 10714816

Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.

M J Wilson1, A R Ruhland, B J Quast, P K Reddy, S L Ewing, A A Sinha.   

Abstract

Dipeptidylpeptidase IV (DPP IV) is a serine exopeptidase that has been implicated in cell-extracellular matrix interactions and bioactive peptide/cytokine/growth factor metabolism. The objective of this study was to determine if DPP IV activities were changed with development of cancer in the prostate. DPP IV activity was measured in human prostate cancer and benign prostatic hyperplasia (BPH) tissues by biochemical assays with glycylprolyl-p-nitroanalide as substrate in tissue extracts (BPH, n = 8: cancer, n = 7; 2 with Gleason score 5 and 5 with Gleason score 7) and quantitative morphometry of histochemical activities with glycylproline-4-methoxy-beta-naphthylamide as substrate (BPH, n = 9: cancer, n = 13, 1 with Gleason score 4, 10 with Gleason score 6, 2 with Gleason score 8) in frozen-tissue sections. Data were analyzed by analysis of variance. The peptidase activity was detected in epithelial but not stromal cells of BPH and cancer tissues, and it was present as a single band of activity of approximately 160 kDa in electrophoretically separated activity blots of the extracts. DPP IV activity was increased approximately twofold in cancer versus BPH tissues as determined by biochemical and quantitative histochemical methods. In addition, DPP IV activity was increased to a similar extent in BPH glands associated with the cancers. These data indicate that DPP IV activity is increased not only in primary prostatic cancers but also in associated BPH glands, suggesting that there may be some local factors produced by cancer cells that influence adjacent BPH epithelial cells to positively affect the immediate growth environment of the cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714816

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  22 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma.

Authors:  Mengzhen Zhang; Liwei Xu; Xiaoling Wang; Beibei Sun; Juan Ding
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

3.  Stromal expression of CD34, α-smooth muscle actin and CD26/DPPIV in squamous cell carcinoma of the skin: a comparative immunohistochemical study.

Authors:  Ayper Kacar; Ata Türker Arikok; Tuba Dilay Kokenek Unal; Evrim Onder; Sema Hucumenoglu; Murat Alper
Journal:  Pathol Oncol Res       Date:  2011-06-15       Impact factor: 3.201

Review 4.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

5.  Decrease in dipeptidyl peptidase IV activity is linked to the efficacy of differentiating compounds in follicular thyroid carcinoma cell lines.

Authors:  E Fröhlich; E Engel; R Wahl
Journal:  Horm Metab Res       Date:  2011-03-16       Impact factor: 2.936

6.  Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy.

Authors:  Congyi Lu; Jason U Tilan; Lindsay Everhart; Magdalena Czarnecka; Steven J Soldin; Damodara R Mendu; Dima Jeha; Jailan Hanafy; Christina K Lee; Junfeng Sun; Ewa Izycka-Swieszewska; Jeffrey A Toretsky; Joanna Kitlinska
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

7.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices.

Authors:  Giulio Ghersi; Qiang Zhao; Monica Salamone; Yunyun Yeh; Stanley Zucker; Wen-Tien Chen
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

8.  CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.

Authors:  Yan-Xi Sun; Elisabeth A Pedersen; Yusuke Shiozawa; Aaron M Havens; Younghun Jung; Jingcheng Wang; Kenneth J Pienta; Russell S Taichman
Journal:  Clin Exp Metastasis       Date:  2008-06-18       Impact factor: 5.150

9.  Comparison of miRNA and gene expression profiles between metastatic and primary prostate cancer.

Authors:  Kaimin Guo; Zuowen Liang; Fubiao Li; Hongliang Wang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

Review 10.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.